{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:52:22Z","timestamp":1762980742210,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00259-019-04361-0","type":"journal-article","created":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T01:08:14Z","timestamp":1561770494000},"page":"2169-2177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET\/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy"],"prefix":"10.1007","volume":"46","author":[{"given":"Mohammad","family":"Abufaraj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Grubm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Haitel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Baltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Wadsak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Pfaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Wiatr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Mitterhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Hartenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,29]]},"reference":[{"key":"4361_CR1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630\u201342.","journal-title":"Eur Urol"},{"key":"4361_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.eururo.2013.05.025","volume":"64","author":"S Punnen","year":"2013","unstructured":"Punnen S, Cooperberg MR, D\u2019Amico AV, Karakiewicz PI, Moul JW, Scher HI, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013;64:905\u201315.","journal-title":"Eur Urol"},{"key":"4361_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1464-410X.2006.06262.x","volume":"98","author":"FK Chun","year":"2006","unstructured":"Chun FK, Briganti A, Shariat SF, Graefen M, Montorsi F, Erbersdobler A, et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int. 2006;98:329\u201334.","journal-title":"BJU Int"},{"key":"4361_CR4","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","volume":"25","author":"AJ Stephenson","year":"2007","unstructured":"Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035\u201341.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"4361_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/0284186X.2010.542174","volume":"50","author":"SF Shariat","year":"2011","unstructured":"Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011;50(Suppl 1):61\u201375.","journal-title":"Acta Oncol"},{"key":"4361_CR6","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2217\/fon.09.121","volume":"5","author":"SF Shariat","year":"2009","unstructured":"Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. Future Oncol. 2009;5:1555\u201384.","journal-title":"Future Oncol"},{"key":"4361_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.eururo.2014.03.019","volume":"67","author":"F Abdollah","year":"2015","unstructured":"Abdollah F, Briganti A, Montorsi F, Stenzl A, Stief C, Tombal B, et al. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol. 2015;67:839\u201349.","journal-title":"Eur Urol"},{"key":"4361_CR8","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.eururo.2010.09.029","volume":"58","author":"F Abdollah","year":"2010","unstructured":"Abdollah F, Sun M, Thuret R, Bud\u00e4us L, Jeldres C, Graefen M, et al. Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer. Eur Urol. 2010;58:882\u201392.","journal-title":"Eur Urol"},{"key":"4361_CR9","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.1158\/1078-0432.CCR-18-0768","volume":"24","author":"B Grubm\u00fcller","year":"2018","unstructured":"Grubm\u00fcller B, Baltzer P, Hartenbach S, D'Andrea D, Helbich TH, Haug AR, et al. PSMA ligand PET\/MRI for primary prostate cancer: staging performance and clinical impact. Clin Cancer Res. 2018;24:6300\u20137.","journal-title":"Clin Cancer Res"},{"key":"4361_CR10","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.juro.2012.08.041","volume":"188","author":"CA Jilg","year":"2012","unstructured":"Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol. 2012;188:2190\u20137.","journal-title":"J Urol"},{"key":"4361_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2967\/jnumed.116.173492","volume":"57","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Beer AJ, Graner F-P, Haller B, Weirich G, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57:1713\u20139.","journal-title":"J Nucl Med"},{"key":"4361_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00259-017-3858-2","volume":"45","author":"B Grubm\u00fcller","year":"2017","unstructured":"Grubm\u00fcller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, et al. 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy \u2013 diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging. 2017;45:235\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4361_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","volume":"38","author":"L Evangelista","year":"2013","unstructured":"Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, et al. Choline PET or PET\/CT and biochemical relapse of prostate cancer. Clin Nucl Med. 2013;38:305\u201314.","journal-title":"Clin Nucl Med"},{"key":"4361_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.eururo.2010.09.004","volume":"59","author":"M Picchio","year":"2011","unstructured":"Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography\/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51\u201360.","journal-title":"Eur Urol"},{"key":"4361_CR15","doi-asserted-by":"publisher","first-page":"38.e9","DOI":"10.1016\/j.urolonc.2013.03.006","volume":"32","author":"NM Passoni","year":"2014","unstructured":"Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, et al. Utility of [11C]choline PET\/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol. 2014;32:38.e9\u201338.e16.","journal-title":"Urol Oncol"},{"key":"4361_CR16","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668\u201374.","journal-title":"J Nucl Med"},{"key":"4361_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/MNM.0000000000000290","volume":"36","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al. Evaluation of PSMA PET\/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015;36:582\u20137.","journal-title":"Nucl Med Commun"},{"key":"4361_CR18","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","volume":"29","author":"JI Epstein","year":"2005","unstructured":"Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228\u201342.","journal-title":"Am J Surg Pathol"},{"key":"4361_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1148\/radiol.2015151516","volume":"277","author":"PM Bossuyt","year":"2015","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology. 2015;277:826\u201332.","journal-title":"Radiology"},{"key":"4361_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"4361_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40644-016-0072-6","volume":"16","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. 68Ga-PSMA ligand PET\/CT in patients with prostate cancer: how we review and report. Cancer Imaging. 2016;16:87.","journal-title":"Cancer Imaging"},{"key":"4361_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1066896916657590","volume":"25","author":"S Rais-Bahrami","year":"2017","unstructured":"Rais-Bahrami S, Tracht JP, McIntosh ER, Lai WS, Gordetsky JB. Complete tissue submission to increase lymph node detection in pelvic lymph node packets submitted for patients undergoing radical prostatectomy and radical cystectomy. Int J Surg Pathol. 2017;25:12\u20137.","journal-title":"Int J Surg Pathol"},{"key":"4361_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","volume":"63","author":"AM H\u00f6vels","year":"2008","unstructured":"H\u00f6vels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387\u201395.","journal-title":"Clin Radiol"},{"key":"4361_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2013.04.019","volume":"64","author":"MH Umbehr","year":"2013","unstructured":"Umbehr MH, M\u00fcntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET\/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64:106\u201317.","journal-title":"Eur Urol"},{"key":"4361_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1084\/jem.20171052","volume":"215","author":"C Kaittanis","year":"2018","unstructured":"Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018;215:159\u201375.","journal-title":"J Exp Med"},{"key":"4361_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","volume":"4","author":"FE von Eyben","year":"2018","unstructured":"von Eyben FE, Picchio M, Eyben v R, Rhee H, Bauman G. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. 2018;4:686\u201393.","journal-title":"Eur Urol Focus"},{"key":"4361_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00259-015-3240-1","volume":"43","author":"FA Verburg","year":"2015","unstructured":"Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, V\u00f6\u00f6 S, et al. Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET\/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2015;43:397\u2013403.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4361_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12894-015-0004-y","volume":"15","author":"A Winter","year":"2015","unstructured":"Winter A, Henke R-P, Wawroschek F. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up. BMC Urol. 2015;15:423.","journal-title":"BMC Urol"},{"key":"4361_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12885-018-5200-1","volume":"19","author":"J Calais","year":"2019","unstructured":"Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized prospective phase III trial of 68Ga-PSMA-11 PET\/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019;19:18.","journal-title":"BMC Cancer"},{"key":"4361_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.eururo.2018.03.013","volume":"75","author":"T Maurer","year":"2018","unstructured":"Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, et al. 99m technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol. 2018;75:659\u201366.","journal-title":"Eur Urol"},{"key":"4361_CR31","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.7150\/thno.18421","volume":"7","author":"CA Jilg","year":"2017","unstructured":"Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, et al. Diagnostic accuracy of Ga-68-HBED-CC-PSMA-ligand-PET\/CT before salvage lymph node dissection for recurrent prostate cancer. Theranostics. 2017;7:1770\u201380.","journal-title":"Theranostics"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04361-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T23:25:44Z","timestamp":1593300344000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04361-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,29]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4361"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04361-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2019,6,29]]},"assertion":[{"value":"26 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have nothing to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statements"}}]}}